UNSPSC 51262602: Imiloxan

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C14H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZJ56PS1DWK, chemically known as 1h-imidazole, 2-((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)-1-ethyl-, (7r-(7alpha,8beta,10beta))- but generally known as imiloxan, which bears US NIH Compound Identifier 133621. European Medicines Agency schedules Imiloxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08149MIG.

UNSPSC 51262602 Imiloxan, a Commodity code, covers pharmaceutical products and related medical supplies procured by state and local health agencies, though recent activity under this code reflects a mismatch between the nominal scope and actual buying patterns. The Seminole County, Florida procurement (IFB60459723LAS, posted June 30, 2026) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually—opioid-reversal medication and harm-reduction equipment—delivered quarterly to a county health building under a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013, posted April 3, 2026) to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, seeking information on direct contracting with self-insured employers and state agencies and value-based pricing models. The code sees activity from state health departments and county health agencies as issuing bodies, though the recent solicitations diverge substantially from the imiloxan product name itself—neither opportunity specifies imiloxan procurement, and the Seminole County IFB centers on naloxone and drug deactivation rather than imiloxan specifically.

Geographic activity appears concentrated in Florida and Texas based on recent opportunities. The Seminole County solicitation (IFB with response deadline July 26, 2023, though posted in 2026) required vendors to submit bids through the county's e-Procurement Portal, maintain workers' compensation and general liability insurance, and comply with E-Verify employment verification and drug-free workplace requirements; the contract was potentially FEMA-funded and included a three-month probationary termination clause. The Texas RFI, with an April 3, 2026 response deadline, functioned as a preliminary market intelligence tool without formal evaluation criteria or binding timelines, designed to inform future RFP development. Neither opportunity specified set-aside designations for disadvantaged enterprises. The code shows limited recent activity, and the disconnect between the nominal imiloxan scope and the naloxone and pharmacy programs actually being solicited suggests that state and local issuers are tagging broadly under pharmaceutical codes rather than assigning precise commodity classifications to specific drug products.